IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Patrick Dawson BAILEY Atty. Ref.: 620-527

Serial No. 10/585,864 Group: 1654

Filed: July 11, 2006 Examiner: Niebauer

For: DRUG DELIVERY SYSTEM

the Amendment in this regard.

* * * * * * * * * *

Commissioner for Patents March 25, 2010 P.O. Box 1450 March 26, 2010 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

The Amendment filed March 24, 2010 states that a revised PTO 1449 Form listing previously-cited art is attached to the Amendment. The revised PTO 1449 Form was not submitted with the Amendment through inadvertent error by the undersigned. A new PTO 1449 Form listing the previously-cited art and newly cited art is attached. The undersigned regrets any confusion which may have been caused by the remarks of

	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on	the merits] <i>N/C</i>
	2.(a)	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement or Rule 17(p) fee)]	97(e) N/C
Ø	2 .(b)	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement or Rule 17(p) fee)]	97(e) \$180.00
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 9 Statement and Rule 17(p) fee), but before final fee pay	

Information Disclosure Statement March 25, 2010

The following are submitted in the above-identified application in compliance with 37 C.F.R. $\S\S$ 1.97 and 1.98:

	-	-			
\boxtimes	4.	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.			
This p	paper	is sut	omitted in accordance with:		
	5.	37 (CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]		
\boxtimes	6.	37 (and	CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];		
		a)	The required Statement made in item 8 below; or		
	\boxtimes	b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.		
	7.		CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) ement <u>and</u> Rule 17(p) fee), but before final fee payment]; and		
		a)	The fee (\$180.00) required by 37 CFR $\S1.17(p)$ is submitted herewith; and		
		b)	The required Statement is stated in item 8 below.		
	8. Statement under 37 CFR 1.97(e)		ement under 37 CFR 1.97(e)		
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or		
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		

Patrick Dawson BAILEY Appln. No. 10/585,864 Information Disclosure Statement March 25, 2010

 Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100